On Thursday, Following Stocks were among the “Top Losers” In U.S. Stock Exchange: CorMedix Inc (NYSEMKT:CRMD), Murphy Oil Corporation (NYSE:MUR), ADTRAN, Inc (NASDAQ:ADTN), Nektar Therapeutics (NASDAQ:NKTR)
CorMedix Inc (NYSEMKT:CRMD)’s shares dwindled -5.03%, and closed at $7.93. The stock has price to sale ratio of 1912.72, however, price to book ratio is 31.72. With recent decline, the year-to-date (YTD) performance reflected a 315.18% gain above last year. During the past month the stocks gain 136.01%, bringing three-month performance to 491.79% and six-month performance to 355.75%. The mean recommendation of analysts for this stock is 2.00. (where 1=Buy, 5=Sale).
CorMedix Inc., a development-stage pharmaceutical and medical device company, intends to in-license, develop, and commercialize therapeutic products for the treatment of cardiorenal and infectious diseases. The company’s product candidates comprise CRMD003 (Neutrolin) and CRMD004, an antimicrobial/antifungal and anticoagulant combination in liquid and gel formulations used for the prevention of catheter-related blood stream infections and maintenance of catheter patency in hemodialysis patients. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix Inc. in January 2007. CorMedix Inc. was founded in 2006 and is based in Bridgewater, New Jersey.
Murphy Oil Corporation (NYSE:MUR), declined -5.01%, and closed at $46.82. The stock volatility for the week is 3.41%, while for the month remained 2.81%. The company holds consensus target price of $48.08.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed 5.73 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 21.10% and Annual EPS growth for the past 5 years is considered as 8.90%.
The mean recommendation of analysts for this stock is 3.10. (where 1=Buy, 5=Sale).
Murphy Oil Corporation operates as an oil and gas exploration and production company worldwide. It explores for and produces crude oil, natural gas, and natural gas liquids. The company was formerly known as Murphy Corporation and changed its name to Murphy Oil Corporation in 1964. Murphy Oil Corporation was founded in 1950 and is headquartered in El Dorado, Arkansas.
ADTRAN, Inc (NASDAQ:ADTN), dipped -4.98%, and closed at $18.80. The company holds the market capitalization of $1.06B. For the last twelve months, the stock was able to keep return on equity at 7.80%, while return on assets at 5.90%, in response to its return on investment at 5.50%. Its 20-day moving average declined -10.16%, below 50-day moving average of -13.29%, below 200-day moving average of -12.31% from the latest market price of $18.80. The mean recommendation of analysts for this stock is 3.10.(where 1=Buy, 5=Sale).
ADTRAN, Inc. manufactures and sells networking and communications equipment worldwide. It operates in two divisions, Carrier Networks and Enterprise Networks. The Carrier Networks division provides broadband access products, such as multi-service access nodes, fiber to the nodes, digital subscriber line access multiplexer products, and distribution point units; optical products, counting optical networking edge, fiber Ethernet access devices, multi-service edge switches, multi-service provisioning platforms, and pluggable optical products; and time division multiplexed (TDM) systems under the Total Access and hiX brand names.
Nektar Therapeutics (NASDAQ:NKTR), dropped -4.96%, and closed at $11.89. The company has the market capitalization of $1.64B. The beta value of the stock is 1.53. On the other hand the stock’s volatility for the week is 5.67%, and for the month is 4.73%. The stock’s price to book ratio is 7.78, however price to sale ratio is 42.46. Analyst’s mean recommendation regarding this stock is 1.80. (where 1=Buy, 5=Sale).
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline comprises drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology. The company offers MOVANTIK, an oral peripherally-acting mu-opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives. Its drug candidates in clinical development stage comprises BAX 855 that is in Phase III clinical trial for treating Hemophilia A; BAY41-6551, which is in Phase III clinical trial to treat gram-negative pneumonias; NKTR-181 that is in Phase III clinical trial for chronic pain; NKTR-171, which is in Phase I clinical trial to treat neuropathic pain; and NKTR-214 that is in research and preclinical trial stage to treat oncology, in addition to MOVANTIK, which is research and preclinical stage for treating chronic pain without constipation.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
